Hostname: page-component-745bb68f8f-l4dxg Total loading time: 0 Render date: 2025-01-21T23:23:35.511Z Has data issue: false hasContentIssue false
  • English
  • Français

Treatment of Alzheimer's Disease: Hopes and Reality

Published online by Cambridge University Press:  18 September 2015

S. Gauthier ,
L. Gauthier ,
R. Bouchard ,
R. Quirion  and
S. Sultan
S. Gauthier*
Affiliation:
McGill Centre for Studies in Aging, Montreal
L. Gauthier
Affiliation:
McGill Centre for Studies in Aging, Montreal
R. Bouchard
Affiliation:
McGill Centre for Studies in Aging, Montreal
R. Quirion
Affiliation:
McGill Centre for Studies in Aging, Montreal
S. Sultan
Affiliation:
McGill Centre for Studies in Aging, Montreal
*
McGill Centre for Studies in Aging, 1650 Cedar Avenue, Room 10830 L.H., Montreal, Quebec, Canada H3G 1A4
Rights & Permissions [Opens in a new window]

Abstract:

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

The relative failure of symptomatic therapeutic trials for Alzheimer's disease using non-selective cholinergic agonists brings about the need for longitudinal studies with parallel designs aimed at disease stabilization, using trophic substances or amyloid suppressors.

Type
Research Article
Information
Canadian Journal of Neurological Sciences , Volume 18 , Issue S3 , August 1991 , pp. 439 - 441
Copyright
Copyright © Canadian Neurological Sciences Federation 1991

References

REFERENCES

1.Gauthier, S, Leblanc, R, Quirion, R, et al. Transmitter-replacement therapy in Alzheimer’s disease using intracerebro-ventricular infusions of receptors agonists. Can J Neurol Sci 1986; 13: 394–402.CrossRefGoogle Scholar
2.Quirion, R, Martel, JC, Robitaille, Y, et al. Neurotransmitter and receptor deficits in senile dementia of the Alzheimer type. Can J Neurol Sci 1986; 13: 503–510.CrossRefGoogle ScholarPubMed
3.Doucette, R, Fisman, M, Hachinski, NC, et al. Cell loss from the Nucleus Basalis of Meynert in Alzheimer’s disease. Can J Neurol Sci 1986; 13: 435–440.CrossRefGoogle ScholarPubMed
4.Etienne, P, Dastoor, D, Gauthier, S, et al. Alzheimer disease: lack of effect of lecithin treatment for 3 months. Neurology 1981; 31: 1552–1554.CrossRefGoogle ScholarPubMed
5. Harbaugh, RE, Reeder, TM, (Leblanc, R), et al. Intracerebroventricular bethanechol chloride infusion in Alzheimer’s disease. J Neurosurg 1989; 71: 481–486.CrossRefGoogle ScholarPubMed
6.Gauthier, S, Bouchard, R, Lamontagne, A, et al. Tetrahydroamino-acridine-lecithin combination treatment in patients with intermediate - stage Alzheimer’s disease. N Engl J Med 1990; 322: 1272–1276.CrossRefGoogle ScholarPubMed
7.Lavori, PW, Louis, TA, Bailar, JC, et al. Designs for experiments - parallel comparisons of treatment. N Engl J Med 1983; 309: 1291–1298.CrossRefGoogle ScholarPubMed
8.Louis, TA, Lavori, PW, Bailar, JC, et al. Cross-over and self controlled designs in clinical research. N Engl J Med 1984; 310: 24–31.CrossRefGoogle Scholar
9.Katzman, R, Brown, T, Thai, LJ, et al. Comparison of rate of annual change of mental status score in four independent studies of patients with Alzheimer’s disease. Ann Neurol 1988; 24: 384–389.CrossRefGoogle ScholarPubMed
10.Stern, Y, Hesdorffer, D, Sano, M, et al. Measurement and prediction of functional capacity in Alzheimer’s disease. Neurology 1990; 40: 8–14.CrossRefGoogle ScholarPubMed
11.Kaszniak, AW, Wilson, RS, Fox, JH, et al. Cognitive assessment in Alzheimer’s disease: Cross-sectional and longitudinal perspectives. Can J Neurol Sci 1986; 13: 420–423.CrossRefGoogle ScholarPubMed
12.Huff, FJ, Belle, SH, Shin, YK, et al. Prevalence and prognostic value of neurologic abnormalities in Alzheimer’s disease. Dementia 1990; 1: 32–40.Google Scholar
13.Crapper, McLachlan D, Dalton, AJ, Galin, H, et al. Alzheimer’s disease: clinical course and cognitive disturbances. Acta Neurol Sand 1984; 60 suppl 99: 83–88.Google Scholar
14.Dastoor, D, Cole, MG. The course of Alzheimer’s disease: an uncontrolled longitudinal study. J Clin Exp Gerontology 1985–86; 7: 289–299.Google Scholar
15.Uhlamnn, RF, Larson, EB, Buchner, DM. Correlations of Mini-Mental State and Modified Dementia Rating Scale to measure transitional health status in dementia. J Gerontology 1987; 42: 33–36.CrossRefGoogle Scholar
16.Gauthier, L, Gauthier, S. Assessment of functional changes in Alzheimer’s disease. Neuroepidemiology 1990; 9: 183–188.CrossRefGoogle ScholarPubMed
17.Grady, CL, Haxby, JV, Horwitz, B, et al. Longitudinal study of the early neuropsychological and cerebral metabolic changes in dementia of the Alzheimer type. J Clin Exp Neuropsychology 1988; 10: 576–596.CrossRefGoogle ScholarPubMed
18.Botwinick, J, Storandt, M, Berg, L. A longitudinal behavioral study of senile dementia of the Alzheimer type. Arch Neurol 1986; 43: 1124–1127.CrossRefGoogle ScholarPubMed
19.The Parkinson Study Group. Effect of Deprenyl on the progression of disability in early Parkinson’s disease. N Engl J Med 1989; 321: 1364–1371.CrossRefGoogle Scholar
20.Drachman, DA, O’Donell, BF, Lew, RA, et al. The prognosis in Alzheimer’s disease: how far rather than how fast best predicts the course. Arch Neurol 1990; 47: 851–856.CrossRefGoogle ScholarPubMed